High-Frequency 10-kHz Spinal Cord Stimulation Provides Long-term (24-Month) Improvements in Diabetes-Related Pain and Quality of Life for Patients with Painful Diabetic Neuropathy
Erika A Petersen,Thomas G Stauss,James A Scowcroft,Michael J Jaasma,Deborah R Edgar,Judith L White,Shawn M Sills,Kasra Amirdelfan,Maged N Guirguis,Jijun Xu,Cong Yu,Ali Nairizi,Denis G Patterson,Michael J Creamer,Vincent Galan,Richard H Bundschu,Neel D Mehta,Dawood Sayed,Shivanand P Lad,David J DiBenedetto,Khalid A Sethi,Johnathan H Goree,Matthew T Bennett,Nathan J Harrison,Atef F Israel,Paul Chang,Paul W Wu,Charles E Argoff,Christian E Nasr,Rod S Taylor,David L Caraway,Nagy A Mekhail
DOI: https://doi.org/10.1177/19322968241268547
2024-10-06
Abstract:Background: The SENZA-PDN study evaluated high-frequency 10-kHz spinal cord stimulation (SCS) for the treatment of painful diabetic neuropathy (PDN). Over 24 months, 10-kHz SCS provided sustained pain relief and improved health-related quality of life. This report presents additional outcomes from the SENZA-PDN study, focusing on diabetes-related pain and quality of life outcomes. Methods: The SENZA-PDN study randomized 216 participants with refractory PDN to receive either conventional medical management (CMM) or 10-kHz SCS plus CMM (10-kHz SCS + CMM), allowing crossover after six months if pain relief was insufficient. Postimplantation assessments at 24 months were completed by 142 participants with a permanent 10-kHz SCS implant, comprising 84 initial and 58 crossover recipients. Measures included the Brief Pain Inventory for Diabetic Peripheral Neuropathy (BPI-DPN), Diabetes-Related Quality of Life (DQOL), Global Assessment of Functioning (GAF), and treatment satisfaction. Results: Over 24 months, 10-kHz SCS treatment significantly reduced pain severity by 66.9% (P < .001; BPI-DPN) and pain interference with mood and daily activities by 65.8% (P < .001; BPI-DPN). Significant improvements were also observed in overall DQOL score (P < .001) and GAF score (P < .001), and 91.5% of participants reported satisfaction with treatment. Conclusions: High-frequency 10-kHz SCS significantly decreased pain severity and provided additional clinically meaningful improvements in DQOL and overall functioning for patients with PDN. The robust and sustained benefits over 24 months, coupled with high participant satisfaction, highlight that 10-kHz SCS is an efficacious and comprehensive therapy for patients with PDN.